China National Accord Medicines Dirección

Dirección controles de criterios 3/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Zhaoxiong Lin

Chief Executive Officer (CEO)

CN¥2.6m

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	8.7yrs
Participación del CEO	n/a
Permanencia media de la dirección	5.4yrs
Promedio de permanencia en la Junta Directiva	3.7yrs

Actualizaciones recientes de la dirección

Recent updates

CEO

Zhaoxiong Lin (57 yo)

8.7yrs

Permanencia

CN¥2,550,000

Compensación

Mr. Zhaoxiong Lin, MBA has been General Manager of Sinopharm Medicine Holding Guangzhou Co., Ltd since December 2006. Mr. Lin has been General Manager of China National Accord Medicines Corporation Ltd. si...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Zhaoxiong Lin	GM & Non-Independent Director	8.7yrs	CN¥2.55m	sin datos
Guolin Gu	Deputy GM	4.5yrs	CN¥1.66m	sin datos
Baochun Lang	General Counsel	6.3yrs	CN¥1.79m	sin datos
Chuan Li	Deputy GM & Board Secretary	less than a year	sin datos	sin datos
Changbing Chen	Deputy General Manager	no data	CN¥1.66m	0.00062% CN¥ 94.7k

5.4yrs

Permanencia media

56yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de 000028 es experimentado (5.4 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Zhaoxiong Lin	GM & Non-Independent Director	8.6yrs	CN¥2.55m	sin datos
Yong Liu	Director	7.8yrs	sin datos	sin datos
Jinxiong Li	Non-Independent Director	less than a year	sin datos	sin datos
Yijian Wu	Chairman of the board	4yrs	sin datos	sin datos
Deyong Wen	Chairman of the Board of Supervisors	5.5yrs	sin datos	sin datos
Weiwei Su	Independent Director	5.8yrs	CN¥250.00k	sin datos
Guojing Chen	Employee Supervisor	6.3yrs	sin datos	sin datos
Xiaojuan Li	Non-Independent Director	3.4yrs	sin datos	sin datos
Honghai Li	Independent Director	less than a year	sin datos	sin datos
Yalin Bi	Independent Director	less than a year	sin datos	sin datos
Haiqing Lu	Supervisor	less than a year	sin datos	sin datos
Bailing Jiang	Independent Director	less than a year	sin datos	sin datos

3.7yrs

Permanencia media

54yo

Promedio de edad

Junta con experiencia: La junta directiva de 000028 se considera experimentada (3.7 años de antigüedad promedio).

China National Accord Medicines Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

High number of new directors

Insufficient new directors

China National Accord Medicines Corporation Ltd., Annual General Meeting, May 08, 2024

China National Accord Medicines Corporation Ltd., Annual General Meeting, Apr 22, 2022

High number of new directors

Recent updates

Third quarter 2024 earnings released: EPS: CN¥0.57 (vs CN¥0.65 in 3Q 2023)

China National Accord Medicines Corporation Ltd. to Report Q3, 2024 Results on Oct 29, 2024

Investor sentiment improves as stock rises 19%

Second quarter 2024 earnings released: EPS: CN¥0.64 (vs CN¥0.84 in 2Q 2023)

High number of new directors

Insufficient new directors

China National Accord Medicines Corporation Ltd. to Report First Half, 2024 Results on Aug 28, 2024

China National Accord Medicines Corporation Ltd. Announces Final Cash Dividend on B Shares for the Year 2023, Payable on 27 June 2024

China National Accord Medicines Corporation Ltd. Approves Cash Dividend for the Year 2023

Now 20% overvalued after recent price rise

First quarter 2024 earnings released: EPS: CN¥0.70 (vs CN¥0.65 in 1Q 2023)

Full year 2023 earnings released: EPS: CN¥2.87 (vs CN¥2.67 in FY 2022)

China National Accord Medicines Corporation Ltd., Annual General Meeting, May 08, 2024

China National Accord Medicines Corporation Ltd. to Report Q1, 2024 Results on Apr 30, 2024

Investor sentiment improves as stock rises 17%

China National Accord Medicines Corporation Ltd. to Report Fiscal Year 2023 Results on Mar 30, 2024

Now 20% undervalued after recent price drop

Now 21% undervalued after recent price drop

Third quarter 2023 earnings released: EPS: CN¥0.65 (vs CN¥0.68 in 3Q 2022)

Second quarter 2023 earnings released: EPS: CN¥0.83 (vs CN¥0.75 in 2Q 2022)

Full year 2022 earnings released: EPS: CN¥3.47 (vs CN¥3.12 in FY 2021)

Investor sentiment improves as stock rises 18%

Now 20% undervalued

Third quarter 2022 earnings released: EPS: CN¥0.88 (vs CN¥0.78 in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.98 (vs CN¥0.96 in 2Q 2021)

China National Accord Medicines Corporation Ltd. Announces 2021 Final Profit Distribution Plan to Be Implemented (A Shares), Payable on June 17, 2022

First quarter 2022 earnings released: EPS: CN¥0.59 (vs CN¥0.77 in 1Q 2021)

China National Accord Medicines Corporation Ltd. Approves Final Cash Dividend for the Year 2021

China National Accord Medicines Corporation Ltd., Annual General Meeting, Apr 22, 2022

China National Accord Medicines Corporation Ltd. Proposes Final Cash Dividend for the Year 2021

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Third quarter 2021 earnings released

Second quarter 2021 earnings released: EPS CN¥0.96 (vs CN¥0.92 in 2Q 2020)

High number of new directors

Upcoming dividend of CN¥0.80 per share

First quarter 2021 earnings released: EPS CN¥0.77 (vs CN¥0.58 in 1Q 2020)

Full year 2020 earnings released: EPS CN¥3.27 (vs CN¥2.97 in FY 2019)

China National Accord Medicines Corporation Ltd. to Report Fiscal Year 2020 Results on Apr 16, 2021

New 90-day low: CN¥41.98

New 90-day high: CN¥51.91

Third quarter earnings released

China National Accord Medicines Corporation Ltd. to Report Q3, 2020 Results on Oct 22, 2020

First half earnings released

First half earnings released

China National Accord Medicines Corporation Ltd. to Report First Half, 2020 Results on Aug 29, 2020

New 90-day high - CN¥51.20

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad